The short version
13 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Buprenorphine
Buprenorphine · BUPRENORPHINE HYDROCHLORIDE 8 mg/1 · Tablet · Sublingual · Unit Dose Solutions, Inc.
NDC 87441-0082-01 · 30 TABLET in 1 BLISTER PACK · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 00054-0177-13) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$0.7549per unit
middle half $0.4742–$1.36 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $0.7549
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 2 · prior auth 0% · step therapy 0% · qty limit 52%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 6 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for buprenorphine (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $246.57 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program · Brixadi
Regulatory
- Application
- ANDA207276
- TE code
- AB
- Approval date
- Mar 27, 2017
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Buprenorphine (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Bryant Ranch Prepack | BUPRENORPHINE HYDROCHLORIDE 2 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Bryant Ranch Prepack | BUPRENORPHINE HYDROCHLORIDE 8 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Clinical Solutions Wholesale, LLC | BUPRENORPHINE HYDROCHLORIDE 2 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| A-S Medication Solutions | BUPRENORPHINE HYDROCHLORIDE 8 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Actavis Pharma, Inc. | BUPRENORPHINE HYDROCHLORIDE 8 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Actavis Pharma, Inc. | BUPRENORPHINE HYDROCHLORIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| American Health Packaging | BUPRENORPHINE HYDROCHLORIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| American Health Packaging | BUPRENORPHINE HYDROCHLORIDE 8 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvPAK | BUPRENORPHINE HYDROCHLORIDE 8 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvPAK | BUPRENORPHINE HYDROCHLORIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Hikma Pharmaceuticals USA Inc. | BUPRENORPHINE HYDROCHLORIDE 8 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Hikma Pharmaceuticals USA Inc. | BUPRENORPHINE HYDROCHLORIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Major Pharmaceuticals | BUPRENORPHINE HYDROCHLORIDE 8 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Major Pharmaceuticals | BUPRENORPHINE HYDROCHLORIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Redpharm Drug | BUPRENORPHINE HYDROCHLORIDE 8 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Remedyrepack Inc. | BUPRENORPHINE HYDROCHLORIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Rhodes Pharmaceuticals LLC | BUPRENORPHINE HYDROCHLORIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Rhodes Pharmaceuticals LLC | BUPRENORPHINE HYDROCHLORIDE 8 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | BUPRENORPHINE HYDROCHLORIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | BUPRENORPHINE HYDROCHLORIDE 8 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Unit Dose Solutions, Inc. | BUPRENORPHINE HYDROCHLORIDE 8 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Unit Dose Solutions, Inc. | BUPRENORPHINE HYDROCHLORIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Clinical Solutions Wholesale, LLC | BUPRENORPHINE HYDROCHLORIDE 8 mg/1 | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Buprenorphine — NDC 87441-0082-01," retrieved September 3, 2026, https://drugdashboards.com/drug/87441008201.
Free to cite with attribution — see how the data is put together.